State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Chimeric antigen receptor T cell (CAR-T) therapy, using autologous T cells redirected toward a tumor-specific antigen, is a useful treatment modality for patients with relapsed/refractory (R/R) hematologic malignancies [1 –3]. The engineered T cells are transduced with a CAR molecule consisting of an antigen recognition single-chain variable fragment (scFv), a transmembrane domain, and an intracellular signaling domain, CD3ζ. The intracytoplasmic and transmembrane portions of a second-generation CAR T cell contain signaling domains of costimulatory receptors involved in T cell activation and durability, including CD3ζ, CD28, 4-1BB, ICOS, and OX40.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research